Evidence map›Paper›PMID 38367964›Full record

ArticleBMJ open2024

User requirements for non-invasive and minimally invasive glucose self-monitoring devices in low-income and middle-income countries: a qualitative study in Kyrgyzstan, Mali, Peru and Tanzania.

Elvis Safary, David Beran, Beatrice Vetter, Molly Lepeska, Aida Abdraimova, Asel Dunganova, Stéphane Besançon, Maria Lazo-Porras, Jill Portocarrero Mazanett, Silvana Pérez-León and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 7 countries.

Elvis SafaryFoundation for Innovative New Diagnostics, Geneva, Switzerland Elvis.Safary@finddx.org.
David BeranDivision of Tropical and Humanitarian Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0001-7229-3920
Beatrice VetterFoundation for Innovative New Diagnostics, Geneva, Switzerland.ORCID 0000-0002-7898-472X
Molly LepeskaHealth Action International, Amsterdam, The Netherlands.
Aida AbdraimovaHealth Policy Analysis Center, Bishkek, Kyrgyzstan.
Asel DunganovaHealth Policy Analysis Center, Bishkek, Kyrgyzstan.
Stéphane BesançonNGO Santé Diabète, Bamako, Mali.
Maria Lazo-PorrasDivision of Tropical and Humanitarian Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-0062-5476
Jill Portocarrero MazanettCRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru.
Silvana Pérez-LeónCRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID 0000-0003-4860-587X
Maria MaixenchsISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Happy NchimbiTanzania NCD Alliance, Dar es Salaam, Tanzania, United Republic of.
Kaushik RamaiyaTanzania NCD Alliance, Dar es Salaam, Tanzania, United Republic of.
Castory MunishiMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of.
Guillermo Z Martínez-PérezFoundation for Innovative New Diagnostics, Geneva, Switzerland.ORCID 0000-0001-6756-9515
FIND · CHPolicy Analysis (United States) · USTanzania Youth Alliance · TZUniversidad Peruana Cayetano Heredia · PEUniversity of Geneva · CHBarcelona Institute for Global Health · ESHealth Action International · NLMali-Folkecenter · MLMuhimbili University of Health and Allied Sciences · TZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDevelopment of non-invasive and minimally invasive glucose monitoring devices (NI-MI-GMDs) generally takes place in high-income countries (HICs), with HIC's attributes guiding product characteristics. However, people living with diabetes (PLWD) in low-income and middle-income countries (LMICs) encounter different challenges to those in HICs. This study aimed to define requirements for NI-MI-GMDs in LMICs to inform a target product profile to guide development and selection of suitable devices.

methodsThis was a multiple-methods, exploratory, qualitative study conducted in Kyrgyzstan, Mali, Peru and Tanzania. Interviews and group discussions/activities were conducted with healthcare workers (HCWs), adults living with type 1 (PLWD1) or type 2 diabetes (PLWD2), adolescents living with diabetes and caregivers.

resultsAmong 383 informants (90 HCW, 100 PLWD1, 92 PLWD2, 24 adolescents, 77 caregivers), a range of differing user requirements were reported, including preferences for area of glucose measurement, device attachment, data display, alert type and temperature sensitivity. Willingness to pay varied across countries; common requirements included ease of use, a range of guiding functions, the possibility to attach to a body part of choice and a cost lower than or equal to current glucose self-monitoring.

conclusionsEase-of-use and affordability were consistently prioritised, with broad functionality required for alarms, measurements and attachment possibilities. Perspectives of PLWD are crucial in developing a target product profile to inform characteristics of NI-MI-GMDs in LMICs. Stakeholders must consider these requirements to guide development and selection of NI-MI-GMDs at country level, so that devices are fit for purpose and encourage frequent glucose monitoring among PLWD in these settings.

Indexed as

Developing CountriesDiabetes Mellitus, Type 2AdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringHumansKyrgyzstanMaliPeruTanzaniaBlood Glucosegeneral diabeteshealth equityhealth services accessibilitypatient-centered carequalitative research

Identifiers

PMID38367964
PMCPMC10875487
OpenAlexW4391899738

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.